- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01262924
Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine
December 16, 2010 updated by: GlaxoSmithKline
A Phase III, Blinded, Randomised, Monocentre, Comparative Clinical Study of the Immunogenicity, Reactogenicity and Safety of a Single Booster Dose of SB Biologicals' Candidate dTpa and pa Vaccines and SB Biologicals' Licensed Td Vaccine in Healthy Adults Aged ≥18 Years
The purpose of this study is to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals' (formerly, SmithKline Beecham Biologicals) reduced-antigen-content acellular pertussis vaccine and reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in comparison with Tedivax-Adult™/ Td-Rix™
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A male or female aged ≥18 years at the time of vaccination
- Free of obvious health problems as established by medical history and clinical examination before entering into the study
- Written informed consent obtained from the subject
- If the subject is female, she must be of non-childbearing potential , i.e., either surgically sterilised or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
For the annex phase of this study, subjects must meet the inclusion criteria mentioned above. In addition, subjects must have received either reduced-antigen-content diphtheria-tetanus or diphtheria-tetanus-acellular pertussis vaccine in the initial phase of the study and not responded to either the diphtheria or tetanus toxoid..
Exclusion Criteria:
- Vaccination against diphtheria and/or tetanus within the previous five years
- Vaccination against pertussis since childhood
- History of diphtheria and/or tetanus
- Known history of pertussis within the previous five years
- Known exposure to diphtheria or pertussis within the previous five years
- Known history of non-response to diphtheria, tetanus or pertussis vaccine
- Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days/ 5 half-lives preceding the dose of study vaccine
- Administration of chronic immunosuppressants or other immune-modifying drugs within six months/ 5 half-lives of vaccination.
- Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before vaccination and ending 30 days after
- Administration of immunoglobulins and/or any blood products within the three months preceding vaccination or planned administration/ administration during the study period
- Any confirmed or suspected immunosuppressive or immunodeficient condition
- Pregnant or lactating female
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
- Hypersensitivity to any component of the vaccines
- Acute disease at the time of enrolment
- Oral temperature of ≥37.5°C (99.5°F)
- Any of the following having occurred after previous administration of diphtheria-tetanus-pertussis vaccine or diptheria and tetanus vaccines
- An immediate anaphylactic reaction
- Signs of encephalopathy
- Any of the following having occurred after previous administration of diphtheria-tetanus-pertussis vaccine alone or in combination with other antigens:
- Rectal temperature ≥40.5°C within 48 hours of vaccination and not due to another identifiable cause
- Collapse or shock-like state within 48 hours of vaccination
- Persistent, inconsolable screaming or crying lasting ≥3 hours within 48 hours of vaccination
- Convulsions with or without fever, occurring within 3 days of vaccination
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
dTPa vaccine
|
Intramuscular, single dose
|
Experimental: Group B
Pa vaccine
|
Intramuscular, single dose
|
Active Comparator: Group C
Tedivax-Adult™/ Td-Rix™
|
Intramuscular, single dose or 2 doses (in the annex phase)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity with respect to components of the study vaccines (in subjects receiving the dTpa vaccine and Tedivax-Adult™/ Td-Rix™)
Time Frame: One month after the booster dose (Month 1)
|
One month after the booster dose (Month 1)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity with respect to components of the study vaccines (in subjects receiving the dTpa, pa vaccines and Tedivax-Adult™/ Td-Rix™)
Time Frame: One month after the booster dose (Month 1)
|
One month after the booster dose (Month 1)
|
Occurrence of solicited local adverse experiences
Time Frame: During the 15-day (Day 0-14) follow-up period after vaccination
|
During the 15-day (Day 0-14) follow-up period after vaccination
|
Occurrence of solicited general adverse experiences
Time Frame: During the 15-day (Day 0-14) follow-up period after vaccination
|
During the 15-day (Day 0-14) follow-up period after vaccination
|
Occurrence of unsolicited symptoms
Time Frame: Within the 31-day (Day 0 -30) follow-up period after vaccination
|
Within the 31-day (Day 0 -30) follow-up period after vaccination
|
Occurrence of any serious adverse experiences
Time Frame: Within the 31-day (Day 0 -30) follow-up period after vaccination
|
Within the 31-day (Day 0 -30) follow-up period after vaccination
|
Lymphoproliferation specific for pertussis toxoid, filamentous haemagglutinin and pertactin/ Cell mediated immunity response
Time Frame: At pre-vaccination (Day 0) and Month 1 post-vaccination
|
At pre-vaccination (Day 0) and Month 1 post-vaccination
|
Immunogenicity with respect to components of the study vaccines (in subjects who did not respond to diphtheria or tetanus toxoid after the first booster dose)
Time Frame: One month after the second and third booster dose (Month 12)
|
One month after the second and third booster dose (Month 12)
|
Occurrence of solicited local adverse experiences (in subjects who did not respond to diphtheria or tetanus toxoid after the first booster dose)
Time Frame: During the 15-day (Day 0-14) follow-up period after the second and third vaccine dose
|
During the 15-day (Day 0-14) follow-up period after the second and third vaccine dose
|
Occurrence of solicited general adverse experiences (in subjects who did not respond to diphtheria or tetanus toxoid after the first booster dose)
Time Frame: During the 15-day (Day 0-14) follow-up period after the second and third vaccine dose
|
During the 15-day (Day 0-14) follow-up period after the second and third vaccine dose
|
Occurrenceof unsolicited symptoms (in subjects who did not respond to diphtheria or tetanus toxoid after the first booster dose)
Time Frame: Within the 31-day (Day 0 -30) follow-up period after vaccination after the second and third vaccine dose
|
Within the 31-day (Day 0 -30) follow-up period after vaccination after the second and third vaccine dose
|
Occurrence of any serious adverse experiences (in subjects who did not respond to diphtheria or tetanus toxoid after the first booster dose)
Time Frame: Within the 31-day (Day 0 -30) follow-up period after vaccination after the second and third vaccine dose
|
Within the 31-day (Day 0 -30) follow-up period after vaccination after the second and third vaccine dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 1997
Primary Completion (Actual)
December 1, 1998
Study Completion (Actual)
December 1, 1998
Study Registration Dates
First Submitted
December 16, 2010
First Submitted That Met QC Criteria
December 16, 2010
First Posted (Estimate)
December 17, 2010
Study Record Updates
Last Update Posted (Estimate)
December 17, 2010
Last Update Submitted That Met QC Criteria
December 16, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Bordetella Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Clostridium Infections
- Corynebacterium Infections
- Whooping Cough
- Tetanus
- Diphtheria
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- 263855/003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diphteria, Tetanus and Pertussis
-
Sanofi Pasteur, a Sanofi CompanyCompletedDiphtheria, Tetanus and PertussisSpain
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis VaccinesAustralia
-
GlaxoSmithKlineTerminatedDiphtheria-Tetanus-Acellular PertussisColombia
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis VaccinesUnited States
-
CanSino Biologics Inc.Active, not recruitingDiphtheria, Tetanus and Acellular PertussisChina
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesKorea, Republic of
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesRussian Federation
-
Sanofi Pasteur, a Sanofi CompanyCompletedTetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)Canada
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | Aspergillosis, Allergic BronchopulmonaryColombia
Clinical Trials on GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine
-
GlaxoSmithKlineCompletedPertussis | Tetanus | Diphtheria
-
GlaxoSmithKlineCompleted
-
Novartis VaccinesCompletedPertussis | Whooping Cough | Tetanus | Diphtheria | LockjawBelgium
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Whooping Cough | Tetanus | DiphtheriaUnited States
-
Mindful Diagnostics and Therapeutics, LLCInfectious Disease Society of AmericaNot yet recruiting
-
SanofiCompletedPertussis | Tetanus | DiphtheriaUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownRheumatoid ArthritisIsrael
-
NovartisNovartis VaccinesCompletedMeningococcal MeningitisUnited States, Italy
-
National Institute of Allergy and Infectious Diseases...Completed
-
Sanofi Pasteur, a Sanofi CompanyTerminatedDengue Fever | Dengue Hemorrhagic FeverPhilippines